Imperative Care Acquires Truvic Medical, Gains New Funding to Support Stroke and PVD Technologies

July 15, 2021—Imperative Care, Inc. announced that it has closed a $260 million Series D financing, the proceeds from will be used to support ongoing commercialization and development of the company’s stroke care technologies and to create a strategic network of development subsidiaries.

The company also announced the acquisition of Truvic Medical, Inc., a peripheral thrombectomy device developer.

Under the terms of the stock-for-stock transaction, Truvic will operate as a wholly owned subsidiary of Imperative Care, retaining its founding leadership team and brand identity. The proceeds from the Series D financing will also be used to advance Truvic’s development and commercialization of technologies for the treatment of peripheral vascular disease.

The financing was led by D1 Capital Partners LP, with new investors HealthCor Investments LLC and Innovatus Capital Partners, LLC, and existing investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures.

The California-based Imperative Care has FDA 510(k) clearances for two product platforms: its Large Distal Platform, a family of access catheters designed to facilitate navigation into blood vessels of the brain; and the Zoom aspiration system, a family of products designed to facilitate clot removal during ischemic stroke. Imperative Care was founded in 2015 by neurointerventionist Nick Hopkins, MD, and medtech entrepreneur Fred Khosravi.